Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Shintaro NakanoYasuyuki KawamotoSatoshi YukiKazuaki HaradaTakuto MiyagishimaSusumu SogabeMasayoshi DazaiAtsushi SatoAtsushi IshiguroMichio NakamuraShinya KajiuraYasuo TakahashiMiki TateyamaKazuteru HatanakaYasushi TsujiTakahide SasakiYoshiaki ShindoTomoe KobayashiIsao YokotaNaoya SakamotoYuh SakataYoshito KomatsuPublished in: BMJ open (2022)
jRCTs011190008.
Keyphrases
- phase ii
- study protocol
- open label
- clinical trial
- double blind
- placebo controlled
- phase iii
- randomized controlled trial
- acute lymphoblastic leukemia
- squamous cell carcinoma
- acute myeloid leukemia
- small cell lung cancer
- diffuse large b cell lymphoma
- multiple myeloma
- hodgkin lymphoma
- locally advanced
- radiation therapy
- chemotherapy induced